Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abrocitinib, accrual, amenable, anticalin, Appellate, Arrowhead, Asana, ASC, ASH, bermekimab, BIOCAD, biopolymer, Bipartisan, bluebird, Blueprint, captured, certiorari, CFDA, Chemistry, chemotherapy, Chengdu, Chinese, CHMP, Chugai, Codification, column, comment, compulsory, conbercept, concept, Congo, Congressional, constrained, construed, contemporaneously, copyright, CRSwNP, curative, Democratic, destroy, diffuse, dispensed, DLBCL, DoD, domain, dostarlimab, estoppel, etiokimab, extracting, faricimab, Fasenra, feedback, fevipiprant, filgotinib, FPC, Garetosmab, Glenmark, Hakko, HRSA, Incyte, inpatient, input, intentionally, introduce, introduced, investigationally, IOI, IPHC, JSC, Kanghong, Kiniksa, Kirin, Kodiak, Kyowa, laid, lebrikizumab, Libatyo, Libtayo, LuciNex, MA, Millennium, Munich, Mycenax, NASH, native, nemolizumab, neuromuscular, nonalcoholic, oncostatin, Ono, outbreak, ovarian, overcharge, owed, PanOptica, PAS, peficitinib, pharmacist, pilot, PMDA, pneumonia, Pozelimab, prepayment, prolonged, pronounced, proof, prostaglandin, PTAB, radiation, ranibizumab, recalculation, referral, REGENXBIO, relapsed, Republic, RNA, rulemaking, run, rural, software, spartalizumab, statutorily, supervision, suspension, tailored, Takeda, Terifay, tezepelumab, therefrom, tislelizumab, transparency, turnover, unsatisfied, upfront, urinary, usability, variant, vicinity, whichever, writ, XBiotech, Xolair
Removed:
Ablynx, abnormality, activation, AD, adjunct, Alder, allocate, alpha, alternate, applying, arthralgia, assignee, Australia, bad, baker, bargaining, binding, Breakthrough, buffer, capitalization, Cayman, cellular, CHD, children, cholesterol, circulating, closed, cognate, collective, colorectal, confirmation, contemplated, cooling, cytokine, decoy, deficit, deliverable, demyelination, deploy, digit, disruptive, dosage, efficient, Eleventh, emerge, ensuing, enzyme, EoE, existed, extracellular, Fargo, Fc, Fifteenth, FOLFIRI, formation, Fourteenth, fulfillment, fused, gemcitabine, Goldman, gout, hierarchy, IDMC, IgE, immunogenicity, Immunoglobulin, inadequately, incidence, indenture, inherited, inhibition, initiating, Inspector, insure, Intermittent, intolerant, intranasal, investee, investigated, irinotecan, landmark, leucovorin, LIBERTY, lipoprotein, literature, loading, Loan, Master, maximally, mCRC, modifying, modulating, morbidity, Morgan, mortality, Mt, Neil, nerve, neurocognitive, OIG, pancreatic, persistent, perspective, persuasive, placental, plasma, PlGF, post, principle, progressed, prospectively, purified, QUEST, RA, recommendation, recurrent, refund, regulating, rendered, resistant, responded, science, securing, separation, Seventeenth, showed, signaling, Sixteenth, soluble, solution, Stahl, standalone, Stanley, stimuli, subunit, Suisse, supplemented, swallowing, Syncytial, Thirteenth, tissue, top, track, Trustee, Twelfth, unamortized, uncontrolled, unknown, unprofitable, uptake, uric, visual, voted, Web, weekly, withheld, withholding
Filing tables
Filing exhibits
- 10-K Annual report
- 10.2.17 Stock Option Agreement (NQ) - Executive Officers
- 10.2.18 Stock Option Agreement (NQ) - P. Roy Vagelos
- 10.2.19 Restricted Stock Agreement - Executive Officers
- 10.2.20 Stock Option Agreement (NQ) - Non-employee Directors
- 10.2.21 Restricted Stock Unit Agreement - Non-employee Directors
- 10.17 Amended and Restated Immuno-oncology Discovery and Development Agreement
- 21.1 Subsidiaries of Regeneron Pharmaceuticals, Inc.
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
Associated REGN transcripts
REGN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-228352) and S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, 333-198794, and 333-218669) of Regeneron Pharmaceuticals, Inc., of our report dated February 7, 2019 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 7, 2019